Major Depressive Disorder (MDD) Archives

Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics

Acquisitions, Analysts, Business, Charcot–Marie–Tooth Disease (CMT), Depression, Essential Tremor, Major Depressive Disorder (MDD), Milestone Payments, Neurological Disorders, Postpartum Depression, Potential Blockbusters, Product Pipeline, Shares, U.S. Centers for Disease Control and Prevention

Biogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.

November 27, 2020/by Reuters Health